Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Income towards Parent Company of -$7.8 million for Q1 2026, down 100.6% year-over-year from $1.3 billion in Q1 2025, and down 11.46% quarter-over-quarter from -$7.0 million in Q4 2025.
Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Income towards Parent Company for 7 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 100.6% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$25.1 million (down 122.38% YoY), while the FY2025 annual figure was -$21.2 million, down 89.66% from the prior year.
- Income towards Parent Company slipped to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$7.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $9.4 million in Q4 2023 and bottomed at -$7.8 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$3.8 million across 5 years, with a median of -$5.0 million in 2025.
- Annual changes were most pronounced in 2023 — Income towards Parent Company soared 251.35% — and 2025, when it slumped 159.74%.
- Vivos Therapeutics' Income towards Parent Company stood at -$6.2 million in 2022, then jumped by 251.35% to $9.4 million in 2023, then plunged by 130.8% to -$2.9 million in 2024, then slumped by 141.04% to -$7.0 million in 2025, then fell by 11.46% to -$7.8 million in 2026.
- Business Quant data shows VVOS's Income towards Parent Company at -$7.8 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn |
| 10 | Vivos Therapeutics | 4.81 Mn | 3.01 Mn | 2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -3.76 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -5.53 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -6.19 Mn |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | -7.41 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.04 Mn |